Mokari Atabak sold $9.2M of CORT
Mokari Atabak (Chief Financial Officer) sold 80,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $114.71 ($105.54–$120.67, $9.18M total) across 13 trades on 2026-07-30 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the insider trading record and may influence short-term sentiment, but it does not provide new company fundamentals.
Market read
A CFO open-market sale of roughly $9.18M in CORT shares under a 10b5-1 plan is disclosed, with likely limited trading impact absent other catalysts.
What to watch
The filing does not disclose whether other insiders or the company announced offsetting catalysts (buybacks, guidance, trial updates), so traders should not infer fundamental deterioration from this alone.
Background
The article is an SEC Form 4 insider transaction report for Corcept Therapeutics, filed by the CFO.
Ticker impact
Corcept Therapeutics CFO Mokari Atabak sold about $9.18M of CORT shares via an open-market sale under a 10b5-1 plan on 2026-07-30.
Likely limited, short-lived sentiment impact; no clear directional catalyst from the filing alone.
The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no accompanying company-specific news (earnings, guidance, deals, or regulatory actions).
Market effects
Minimal. Insider sales under 10b5-1 typically do not reset sector fundamentals.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, the transaction may reflect liquidity planning rather than bearish expectations, so any price reaction may be overdone.
Key entities
- issuerCorcept Therapeutics Inc
Subject of the Form 4 insider transaction disclosure.
- insiderMokari Atabak
Chief Financial Officer who sold shares.
